Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 11/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CCNH | P51946 | 1/20 | 0.48 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620367 | 0.81 | FYN (0.76) | FYNCHEK2MKNK1MAP4K4CHEK1 | |
| SCHEMBL4621282 | 0.81 | FYN (0.70) | FYNCHEK2MKNK1MAP4K4CHEK1 | |
| SCHEMBL30368662 | 0.81 | AXL (0.76) | FYNCHEK2CHEK1CCNT1CDK8 | |
| SCHEMBL29004627 | 0.81 | AXL (0.76) | FYNCHEK2CHEK1CCNT1CDK8 | |
| SCHEMBL13968138 | 0.80 | FYN (0.69) | FYNCHEK2MKNK1MAP4K4CHEK1 | |
| SCHEMBL1679425 | 0.79 | PRKD3 (0.67) | FYNCHEK2MAP4K4 | |
| SCHEMBL13977197 | 0.78 | CHEK2 (0.66) | FYNCHEK2MKNK1MAP4K4CHEK1 | |
| SCHEMBL18613286 | 0.77 | FYN (1.00) | FYNCHEK2MKNK1MAP4K4 | |
| SCHEMBL30521785 | 0.77 | FYN (1.00) | FYNCHEK2MKNK1MAP4K4 | |
| SCHEMBL2224294 | 0.77 | FYN (0.72) | FYNCHEK2MKNK1MAP4K4CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | FYN 1665/4885CHEK2 587/4885MKNK1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.